Mizuho reiterates Outperform rating on Waystar stock after Iodine deal
PositiveFinancial Markets

Mizuho has reaffirmed its Outperform rating on Waystar's stock following the company's recent acquisition of Iodine. This move is significant as it highlights Mizuho's confidence in Waystar's growth potential and strategic direction. Investors may see this as a positive indicator for the company's future performance, especially in the competitive landscape of healthcare technology.
— Curated by the World Pulse Now AI Editorial System